Jill Canada Appointed VP of Corporate and Enterprise Sales at Avail Medsystems

Ms. Canada Will Guide Device Industry and Healthcare System Clients in Using Avail's Surgical Telepresence Platform to Solve Business Challenges

Avail Medsystems, a pioneering healthcare technology company whose innovative surgical telepresence platform facilitates real-time collaboration between medical professionals during live procedures, announced today that it has named Jill Canada its Vice President of Corporate and Enterprise Sales.

A recognized commercial leader who has spent nearly 20 years helping clients gain a competitive advantage by developing strategies to strengthen revenue and operating margin, Jill Canada will lead a team at Avail in fostering supportive, productive relationships with key medical device industry and healthcare system clients.

“By putting industry experts in procedure rooms when they can’t otherwise be on site, we’re enabling access to expertise not just when it’s convenient, but when needed,” Avail Founder and CEO Daniel Hawkins said. “Jill’s consultative approach is an ideal fit for our medical device and health system clients as they look to implement digital solutions to make servicing their physician customers and patients more efficient and effective.”

“The team at Avail is one of the most committed groups I’ve seen during my career, united by a passion to improve healthcare through technology. Jill is the perfect complement,” stated Ryan Magnes, President, Avail. “She brings the experience necessary to connect the right clients with solutions to support their efforts to standardize access to excellent healthcare, improve physician satisfaction, reduce costs, and expand reach of the most relevant experts.”

Since 2013, Ms. Canada has worked for GE Healthcare, most recently as Executive, Strategic Clients and before that as Senior Director, Strategic Clients. Prior to GE, Jill was a Strategic Account Specialist for Roche Diagnostics and Vice President of Business Development for SafeScan Imaging Services.

“I’m thrilled to join the team at Avail, where my goal is to help improve the way healthcare is delivered,” Ms. Canada said. “I’m committed to leading a team that cultivates true partnerships, fostering the success of pivotal healthcare stakeholders through the application of Avail’s telepresence platform. My work will be fueled by Avail’s mission to level the playing field for treatment facilities, physicians, and patients everywhere by bringing the world’s clinical expertise into any procedure room, anytime, at the click of a button.”

With Ms. Canada’s hire, Avail furthers its continued organizational expansion including moving from a business incubator into a larger headquarters in May 2021, a $100 million Series B funding round, the ongoing expansion of contracts with medical device industry clients, and the addition of console locations across the US.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”